2025 Q4
2025-11-19
2026 Annual Bonus Plan and Performance Share Programs Adopted
Awards to certain executive officers under both programs are subject to discretionary recoupment policy
View Filing →
2025-10-23
Director John E. Sununu Not Standing for Re-election
John E. Sununu departing 2026 Annual Meeting after 17 years
View Filing →
2025-10-22
Q3 Earnings
Q3 2025 financial results for quarter ended Sept 30, 2025
View Filing →
2025 Q3
2025-09-04
EVP Peripheral Interventions Retired
Jeffrey B. Mirviss retiring Dec 1, 2025, $705K base salary
View Filing →
2025-07-23
Q2 Earnings
Q2 2025 financial results announced
View Filing →
2025 Q2
2025-05-28
Discontinued ACURATE Valve Systems
Worldwide discontinuation of ACURATE neo2 and Prime Aortic Valve Systems
View Filing →
2025-05-06
2025 Annual Shareholder Meeting Results
All 10 directors elected, say-on-pay approved, simple majority vote proposal passed
View Filing →
2025-04-23
Q1 2025 Earnings
Q1 2025 financial results announced
View Filing →
2025-04-23
CFO Transition
Daniel Brennan retiring as CFO, Jonathan Monson promoted effective June 30
View Filing →
2025 Q1
2025-02-26
Euro Debt Offering
€1.5B notes issued (€850M 2031 at 3.0%, €650M 2034 at 3.25%)
View Filing →
2025-02-12
Director Not Standing for Re-election
Charles J. Dockendorff stepping down after 10 years
View Filing →
2025-02-05
Q4 2024 Earnings
Q4 and full year 2024 financial results announced
View Filing →
2025-01-16
LOTUS Edge Valve Settlement
Court preliminary approval Jan 8, final hearing Mar 25
View Filing →
2024 Q4
2024-11-22
2025 Compensation Plans Approved
Annual bonus plan with 0-225% payout range, performance shares with 0-200% range
View Filing →
2024-11-15
Acquired Axonics Inc
$3.7B equity value, $71/share cash
View Filing →
2024-11-07
Resumed AVANT GUARD Clinical Trial
Trial studying drug-naïve patients with persistent atrial fibrillation resumed after data monitoring committee assessment
View Filing →
2024-10-23
Q3 Earnings
Q3 2024 financial results for quarter ended Sept 30
View Filing →
2024 Q3
2024-07-30
New Director Appointed
David C. Habiger appointed to Board, ~$256K prorated compensation
View Filing →
2024-07-24
Q2 2024 Earnings
Q2 2024 financial results announced
View Filing →
2024 Q2
2024-05-10
New Director Appointed & Credit Line Extended
Dr. Cheryl Pegus joins board, $2.75B credit facility extended to 2029
View Filing →
2024-05-06
Annual Shareholder Meeting
9 directors elected, bylaws amended for proxy rules
View Filing →
2024-04-24
Q1 Earnings
Q1 2024 financial results for quarter ended March 31, 2024
View Filing →
2024 Q1